ArticleOncology letters2014
Association between FOXP3 promoter polymorphisms and cancer risk: A meta-analysis.
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The association ofBioscience reports · 2019Pooled it
- Functional Foxp3 polymorphisms and the susceptibility to cancer: An update meta-analysis.Medicine · 2018Pooled it
- Association between tumor necrosis factor-α gene polymorphisms and diffuse large B-cell lymphoma in Chinese Han population: evidence from two center case-control study and a meta-analysis.International journal of clinical and experimental pathology · 2015Pooled it
- FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.European journal of clinical pharmacology · 2017Trial
- FOXP Transcription Factors in Thyroid Cancer: From Molecular Expression to Clinical Significance.Biomedicines · 2026Review
- A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers.Computational and structural biotechnology journal · 2025Article
- Genetic and Epigenetic Association ofInternational journal of molecular sciences · 2024Article
- Forkhead Box Protein P3 (FOXP3) Represses ATF3 Transcriptional Activity.International journal of molecular sciences · 2021Article
- Assessment of the Relationship between Ulcerative Colitis and Forkhead Box P3 Polymorphisms.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- The role of FOXP3 rs3761548 and rs2294021 polymorphisms in pediatrics acute lymphoblastic leukemia: association with risk and response to therapy.Molecular biology reports · 2021Article
- Epigenetic Alteration and its Association With Downregulated FOXP3 Gene in Indian Breast Cancer Patients.Frontiers in genetics · 2021Article
- Article
- Association of FOXP3 Single Nucleotide Polymorphisms With Clinical Outcomes After Allogenic Hematopoietic Stem Cell Transplantation.Annals of laboratory medicine · 2018Article
- Fc receptor-like 3 (-169T>C) polymorphism increases the risk of tendinopathy in volleyball athletes: a case control study.BMC medical genetics · 2018Article
- FOXP3 Activates SUMO-ConjugatingInternational journal of molecular sciences · 2018Article
- The -Frontiers in immunology · 2018Article
- Association of twoCancer management and research · 2018Article
- Inherent X-Linked Genetic Variability and Cellular Mosaicism Unique to Females Contribute to Sex-Related Differences in the Innate Immune Response.Frontiers in immunology · 2017Article
- Article
- Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.Molecular and clinical oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies have been conducted to investigate the association between the FOXP3 promoter polymorphisms, rs3761549 and rs3761548, and the risk of cancer. However, the results from these studies have been controversial. In order to obtain a more precise conclusion of this association, the present meta-analysis was performed. The odds ratio (OR) and 95% confidence interval (95% CI) values were used to assess any correlations between the data. Overall, the rs3761549 (C>T) and rs3761548 (C>A) polymorphisms of the FOXP3 gene were not associated with the cancer risk in an Asian population. In the subgroup analyses based on cancer type, no significant associations were identified between these two polymorphisms and breast cancer. However, the results altered when the analyses were restricted to hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) (for rs3761549: TT+CT vs. CC OR, 0.52, 95% CI, 0.38-0.72; TC vs. CC OR, 0.25, 95% CI, 0.16-0.39; T vs. C OR, 0.76, 95% CI, 0.59-0.97. For rs3761548: AA vs. AC+CC OR, 3.20, 95% CI 1.76-5.81; AA+AC vs. CC OR, 2.56, 95% CI, 1.75-3.76; AA vs. CC OR, 4.41, 95% CI, 2.36-8.25; AC vs. CC OR, 2.15, 95% CI, 1.42-3.25; A vs. C OR, 2.32, 95% CI, 1.74-3.10). The present meta-analysis indicates that the FOXP3 rs3761549 (C>T) and rs3761548 (C>A) polymorphisms are not associated with the risk of breast cancer, but with the risk of HCC and NSCLC. Therefore, a study with a larger sample size is required to further evaluate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.